United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of “Moderate Buy” from Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $509.50.

A number of brokerages have recently commented on UTHR. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. UBS Group lifted their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $470.43, for a total transaction of $10,584,675.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 519,364 shares of company stock worth $248,945,392 in the last ninety days. 10.30% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

Large investors have recently modified their holdings of the company. Clearstead Advisors LLC lifted its holdings in shares of United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the period. Bessemer Group Inc. raised its holdings in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 28 shares in the last quarter. Archer Investment Corp raised its holdings in shares of United Therapeutics by 9.5% in the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 31 shares in the last quarter. F m Investments LLC lifted its stake in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 33 shares during the period. Finally, HB Wealth Management LLC grew its holdings in United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 1.2%

UTHR stock opened at $475.00 on Tuesday. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $519.99. The firm has a market capitalization of $20.45 billion, a P/E ratio of 18.00, a price-to-earnings-growth ratio of 2.50 and a beta of 0.85. The company has a fifty day simple moving average of $487.22 and a two-hundred day simple moving average of $423.14.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.